Wells Fargo lowered the firm’s price target on GoodRx (GDRX) to $7 from $8 and keeps an Overweight rating on the shares. The firm’s discount Rx benchmark crowns GoodRx as the best discount platform, across both depth and breadth of generic Rx discounts, but competitive gap appears to be narrowing, likely limiting upside to the core business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Holdings: Strategic Positioning and Cost Advantages Support Buy Rating Amidst Competitive Landscape
- GoodRx price target lowered to $5.50 from $6.50 at Truist
- Cautious Outlook for GoodRx Holdings Amid Limited Partnership Impact and Industry Challenges
- Balanced Outlook on GoodRx Holdings: Growth Potential Amidst Cautious Market Expectations
- GoodRx Holdings: Buy Rating Affirmed Amidst Promising Profit Growth and Strategic Leadership